SB 421: Opioids - As enacted, clarifies that a physician licensed in this state is the only healthcare provider authorized to prescribe a buprenorphine product for a FDA-approved use in recovery or medication-assisted treatment; revises criteria for providers not licensed in this state to prescribe a buprenorphine product for the treatment of opioid use disorder. - Amends TCA Title 33; Title 41; Title 53 and Title 63.

Plain-language summary

SB 421 is a bill introduced in the Tennessee Senate on January 28, 2025. According to its official title, it concerns: Opioids - As enacted, clarifies that a physician licensed in this state is the only healthcare provider authorized to prescribe a buprenorphine product for a FDA-approved use in recovery or medication-assisted treatment; revises criteria for providers not licensed in this state to prescribe a buprenorphine product for the treatment of opioid use disorder. - Amends TCA Title 33; Title 41; Title 53 and Title 63. Primary sponsor: Reeves. Most recent recorded action (April 28, 2025): Comp. became Pub. Ch. 295.

Generated automatically from the official title, sponsor list, and status record only. It does not characterize the bill’s purpose or effects. How summaries are written